Profile - RZONF - OTC PK

Rize Oncology Inc. RZONF

$0.16 $0.159639,900.00% OTC PK

Recommendation

Prev Close

$0.16

Volume

5,000

Avg Vol (90D)

Market Cap

$12.12M

Dividend & Yield

52-Week Range

$0.0004 - $0.16

P/E (TTM)

EPS (TTM)

-$0.0141

My Lists My Alerts

Corporate Info

Website

rizeoncology.com

Phone Number

514-796-2640

Address

301 – 1665 Ellis Street
Kelowna, BC V1Y 2B3

Country

Canada

Year Founded

2018

Details

Sector

Health Care

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Employees

Business Decription

Rize Oncology Inc. engages in the development of oncology therapeutics. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.